<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321476</url>
  </required_header>
  <id_info>
    <org_study_id>Carotid</org_study_id>
    <nct_id>NCT01321476</nct_id>
  </id_info>
  <brief_title>Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis</brief_title>
  <acronym>Carotid</acronym>
  <official_title>Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piedmont Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Piedmont Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use excess tissue from endoscopic or surgical procedures to examine the&#xD;
      elements of plaque that are found in the carotid walls of patients who have a type of heart&#xD;
      and blood vessel disease called atherosclerosis. Tissue will be collected from patients&#xD;
      undergoing carotid procedures as well as patients undergoing liver and/or intestinal&#xD;
      biopsies. This lab study will examine the different types of proteins that play a role in&#xD;
      developing heart plaque.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was never initiated and internal decision to discontinue initiation process&#xD;
  </why_stopped>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrated Plaques</measure>
    <time_frame>up to 30 months</time_frame>
    <description>Presence of both liver and intestinally derived lipoprotein particles demonstrated in human atherosclerotic plaques.</description>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Carotid artery tissue Liver biopsy tissue Intestinal biopsy tissue Cell cultures&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing a carotid, liver, and/or intestinal biopsy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Scheduled for a clinically indicated, standard-of-care carotid endarterectomy (CEA) OR&#xD;
             scheduled for a clinically indicated, standard-of- care surgical, laparoscopic or&#xD;
             endoscopic intestinal biopsy or excision OR scheduled for a clinically indicated,&#xD;
             standard-of-care surgical, laparoscopic or endoscopic liver biopsy or partial&#xD;
             resection/excision&#xD;
&#xD;
          -  Ability and willingness to consent and Authorization for use of PHI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age ≤18 years&#xD;
&#xD;
          -  Inability or unwillingness to consent and Authorization for use of PHI&#xD;
&#xD;
          -  FOR CAROTID PATIENTS - history of carotid trauma, that is determined by the Principal&#xD;
             Investigator to significantly have changed the carotid tissue structure&#xD;
&#xD;
          -  FOR CAROTID PATIENTS - history of middle- or large-vessel vasculitis, that is&#xD;
             determined by the Principal Investigator to significantly have changed the carotid&#xD;
             tissue structure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Heart Institute/Piedmont Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2011</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <name_title>Joseph Miller, MD</name_title>
    <organization>Piedmont Heart Institute</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

